Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate

Executive Summary

FDA user fee reauthorization eliminates limits on waivers, which may ease the burden on FDA to fill open seats on its advisory committees. Vacancy rates have been as high as 24% in FY 2012.

Advertisement

Related Content

CDER Advisory Committee Staffing Improves, But Trouble Spots Remain
CDER Advisory Panel Vacancies Remain High As Overall FDA Rates Improve
Sanofi Takes Another Step Forward In MS, Files Lemtrada NDA
J&J’s Canagliflozin Positive Phase III Data In The Limelight At ADA
User Fee Bills: After Mark-ups, How Will House And Senate Reconcile Differences?
Conflict Of Interest Rules Get Clean Sweep In House Draft User Fee Bill
Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel